ABOUT ESPERO (Espero BioPharma)
We named our company Espero because it means hope. And that’s what we seek to provide everyone who takes our innovative cardiovascular medicines. Hope for improved health and hope for a better tomorrow.
Espero is a biopharmaceutical company focusing on the late-stage development and commercialization of medicines to treat cardiovascular diseases, the leading cause of death worldwide. Recently, Espero merged with Armetheon, Inc., a privately-held, specialty pharmaceutical company developing innovative medicines, initially in thrombosis (tecarfarin) and cardiac arrhythmias (budiodarone). The Company also markets and distributes three in-market standard of care cardiovascular drugs: GoNitroTM (nitroglycerin) sublingual powder (antianginal), Durlaza® (aspirin) Extended Release Capsules, and Nitrolingual® Pumpspray (antianginal).
Espero Biopharma’s late-clinical stage oral anticoagulant candidate – Tecarfarin – addresses a major unmet need – a medication with potentially fewer adverse and fatal drug reactions and expected compatibility with treatment plans for patients with prosthetic heart valves.
Budiodarone is a clinical-stage oral drug candidate that is being investigated for its potential to suppress life-threatening ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs). Budiodarone reduced AF burden in a dose-dependent fashion with up to 75% reduction in the highest dose group in a Phase 2 study with 72 patients with atrial fibrillation.
Educating the Community
As we advance the clinical stages of testing for tecarfarin and budiodarone, we are sharing our story with healthcare providers at appropriate peer-reviewed forums.
Learn More Today
As we complete the late clinical stage for Tecarfarin, we’d like to share our story with healthcare providers. Physicians and their patients could benefit from Espero Biopharma’s novel drug development approach. Please contact us for more information.